These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
111 related articles for article (PubMed ID: 17057183)
1. The international intravitreal bevacizumab safety survey. Ziemssen F; Grisanti S; Bartz-Schmidt KU Br J Ophthalmol; 2006 Nov; 90(11):1440-1. PubMed ID: 17057183 [No Abstract] [Full Text] [Related]
2. Retinal pigment epithelial tear following intravitreal bevacizumab injection for neovascular age-related macular degeneration. Gelisken F; Ziemssen F; Voelker M; Bartz-Schmidt KU Acta Ophthalmol Scand; 2006 Dec; 84(6):833-4. PubMed ID: 17083554 [No Abstract] [Full Text] [Related]
3. Case of anterior uveitis after intravitreal injection of bevacizumab. Pieramici DJ; Avery RL; Castellarin AA; Nasir MA; Rabena M Retina; 2006 Sep; 26(7):841-2. PubMed ID: 16963867 [No Abstract] [Full Text] [Related]
4. Rapid progression of subclinical age-related macular degeneration in the untreated fellow eye after intravitreal bevacizumab. Yoon YH; Kim JG; Chung H; Lee SY Acta Ophthalmol; 2009 Sep; 87(6):685-7. PubMed ID: 18705680 [No Abstract] [Full Text] [Related]
5. Our experience after 1765 intravitreal injections of bevacizumab: the importance of being part of a developing story. Quiroz-Mercado H; Ustariz-González O; Martinez-Castellanos MA; Covarrubias P; Dominguez F; Sanchez-Huerta V Semin Ophthalmol; 2007; 22(2):109-25. PubMed ID: 17564934 [TBL] [Abstract][Full Text] [Related]
6. Primary intravitreal bevacizumab for subfoveal choroidal neovascularization in age-related macular degeneration: results of the Pan-American Collaborative Retina Study Group at 12 months follow-up. Arevalo JF; Fromow-Guerra J; Sanchez JG; Maia M; Berrocal MH; Wu L; Saravia MJ; Costa RA; Retina; 2008; 28(10):1387-94. PubMed ID: 18827735 [TBL] [Abstract][Full Text] [Related]
7. The International Intravitreal Bevacizumab Safety Survey: using the internet to assess drug safety worldwide. Fung AE; Rosenfeld PJ; Reichel E Br J Ophthalmol; 2006 Nov; 90(11):1344-9. PubMed ID: 16854824 [TBL] [Abstract][Full Text] [Related]
8. Controversies in the treatment of wet age-related macular degeneration. Moreno SF; Paloma JB Am J Ophthalmol; 2008 May; 145(5):937; author reply 938. PubMed ID: 18435977 [No Abstract] [Full Text] [Related]
9. Short-term safety and efficacy of intravitreal bevacizumab (Avastin) for neovascular age-related macular degeneration. Rich RM; Rosenfeld PJ; Puliafito CA; Dubovy SR; Davis JL; Flynn HW; Gonzalez S; Feuer WJ; Lin RC; Lalwani GA; Nguyen JK; Kumar G Retina; 2006; 26(5):495-511. PubMed ID: 16770255 [TBL] [Abstract][Full Text] [Related]
10. Intravitreal bevacizumab. Lucas RS; McKee HD; Lee LR Ophthalmology; 2007 Feb; 114(2):400; author reply 400-1. PubMed ID: 17270701 [No Abstract] [Full Text] [Related]
11. Bevacizumab local complications. Gordon-Angelozzi M; Velez-Montoya R; Fromow-Guerra J; García-Aguirre G; Guerrero-Naranjo JL; Quiroz-Mercado H; Morales-Cantón V Ophthalmology; 2009 Nov; 116(11):2264.e1-3. PubMed ID: 19883862 [No Abstract] [Full Text] [Related]
12. Intravitreal bevacizumab for occult choroidal neovascularization with pigment epithelium detachment in age-related macular degeneration. Bom Aggio F; Eid Farah M; Melo GB Acta Ophthalmol Scand; 2006 Oct; 84(5):713-4. PubMed ID: 16965511 [No Abstract] [Full Text] [Related]
13. Acute retinal pigment epithelial tear following intravitreal bevacizumab (Avastin) injection for occult choroidal neovascularisation secondary to age related macular degeneration. Meyer CH; Mennel S; Schmidt JC; Kroll P Br J Ophthalmol; 2006 Sep; 90(9):1207-8. PubMed ID: 16929069 [No Abstract] [Full Text] [Related]
14. Retinal pigment epithelial tear after intravitreal bevacizumab injection. Shah CP; Hsu J; Garg SJ; Fischer DH; Kaiser R Am J Ophthalmol; 2006 Dec; 142(6):1070-2. PubMed ID: 17157598 [TBL] [Abstract][Full Text] [Related]